A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2013

Conditions
Heart Failure
Interventions
BIOLOGICAL

Mesenchymal Precursor Cells (MPCs)

25 M allogeneic MPCs by transendocardial injection and mapping.

BIOLOGICAL

Mesenchymal Precursor Cells (MPCs)

75 M allogeneic MPCs by transendocardial injection and mapping.

BIOLOGICAL

Mesenchymal Precursor Cells (MPCs)

150 M allogeneic MPCs by transendocardial injection

PROCEDURE

standard-of-care treatment with mock mapping and injection procedures.

Mock

PROCEDURE

standard-of-care treatment with mock mapping and injection procedures.

Mock

PROCEDURE

standard-of-care treatment with mock mapping and injection procedures.

Mock

Trial Locations (6)

15213

UPMC, Pittsburgh

77030

Texas Heart Institue, Houston

85297

Mercy Gilbert Medical Center, Gilbert

98122

Swedish Heart and Vascular Institute, Seattle

92037-1300

University of California, San Diego, La Jolla

55407-1139

Minneapolis Heart Institute 920 East 28th St, Suite 300, Minneapolis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mesoblast, Ltd.

INDUSTRY